Biochemical evaluation of the results of lipid regulating treatment in France;Évaluation biologique des résultats du traitement hypolipémiant en France

Archives des Maladies du Coeur et des Vaisseaux

Volumn 98, Issue 1, 2005, Pages 58-62

  Ferrieres J ^a   Lablanche, J M ^b   Pouchain, D ^c   Girerd, X ^d   Krempf, M ^d,e   Nguyen, G ^d,f   Glanddier, P Y ^d,g  

^a CHU RANGUEIL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Recherche en Medecine Generale ^*  (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f Gemba Lifesciences   (France)

^g FNORS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; FRANCE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; REVIEW; TREATMENT OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; EPIDEMIOLOGY; MIDDLE AGED; RISK FACTOR; STATISTICS;

AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; FRANCE; HEALTH CARE SURVEYS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; TREATMENT OUTCOME;

EID: 14744276915     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
2. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Enql J Med 1998; 339: 1349-57.
6. La prise en charge thérapeutique du patient dyslipidémique. AFSSAPS septembre 2000
7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European Society of Cardiology Committee for practice guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10.
10. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67
11. Ferrières J, Cambou JP, Grenier O, Cantet C, Thomas D, Danchin N. Statins after an acute coronary syndrome: the French nation-wide PREVENIR survey. Cardiovasc Drugs Ther 2001; 15: 559-60.
12. Danchin N, Grenier O, Ferrières J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 2002; 88: 159-62.
13. Steg PG, Iung B, Feldman LJ et al. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart 2002; 88: 20-4.
14. Amouyel P, Farnier M, Lyon G et al. Prise en charge des dyslipidémies diagnostiquées en médecine générale en France. Etude PRAGMA. Arch Mal Cœur 2001; 94: 1045-53.
15. Ferrières J, Elbaz M, Maupas E, Carrié D, Puel J. Insuffisance de la prise en charge thérapeutique des patients dyslipidémiques en France: résultats de l'étude ODYSSEE. Arch Mal Cœur 2004; 97: 187-93.
16. Vanuzzo D, Pilotto L, Ambrosio GB et al. EUROASPIRE Study Group. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. Atherosclerosis 2000; 153: 505-17.
17. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
18. Delahaye F, Bory M, Cohen A et al. Groupe épidémiologie et prévention. Recommandations de la Société française de cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë. Arch Mal Cœur 2001; 94: 697-738.
19. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
20. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-70.